AbbVie announced on July 29, 2026, that the European Commission has approved upadacitinib (RINVOQ) for two new indications: severe alopecia areata and non-segmental vitiligo in adult and adolescent patients aged 12 years and older.
The dual approval extends the label of the oral selective JAK1 inhibitor to 10 immune-mediated conditions in the European Union. Upadacitinib was first approved in the United States in 2019 and is now indicated for atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, giant cell arteritis, and the two newly added dermatologic indications.
Mechanism of Action
Upadacitinib is an oral, selective Janus kinase (JAK) inhibitor engineered to preferentially inhibit JAK1. According to AbbVie, enzymatic and cellular assays suggest greater inhibitory potency against JAK1 than against JAK2, JAK3, or TYK2.
Severe Alopecia Areata
The label expansion in alopecia areata is supported by two replicate Phase III studies in the UP-AA program, with topline data disclosed in April 2026. Enrolled patients had a mean baseline Severity of Alopecia Tool (SALT) score of 84, corresponding to roughly 16% scalp hair coverage.
Table 1. UP-AA Phase III Efficacy Endpoints
|
Endpoint |
Upadacitinib 15 mg |
Upadacitinib 30 mg |
Placebo |
|
Study 1 — SALT ≤ 20 at week 24 |
45.2% |
55.0% |
1.5% |
|
Study 1 — SALT ≤ 20 at week 52 |
59.3% |
63.8% |
— |
|
Study 1 — SALT = 0 at week 24 |
14.1% |
20.3% |
0% |
|
Study 1 — SALT = 0 at week 52 |
28.5% |
35.8% |
— |
|
Study 2 — SALT ≤ 20 at week 24 |
44.6% |
54.3% |
3.4% |
|
Study 2 — SALT ≤ 20 at week 52 |
55.0% |
63.3% |
— |
|
Study 2 — SALT = 0 at week 24 |
13.1% |
22.5% |
0.7% |
|
Study 2 — SALT = 0 at week 52 |
26.6% |
37.0% |
— |
Fig. 1.SALT ≤ 20 Indicates 80% or Greater Scalp Hair Coverage; SALT = 0 Indicates Complete Regrowth. Both UP-AA Studies Met Their Primary Endpoints, and Both Dose Arms Were Reported to be Superior to Placebo at Week 24
Non-Segmental Vitiligo
The vitiligo indication is supported by the Viti-Up Phase III program, with results released in October 2025, evaluating upadacitinib 15 mg once daily.
Table 2. Viti-Up Phase III Endpoints at Week 48
|
Endpoint |
Upadacitinib 15 mg |
Placebo |
|
Viti-Up Study 1 — T-VASI 50 |
19.4% |
5.9% |
|
Viti-Up Study 1 — F-VASI 50 |
25.2% |
5.9% |
|
Viti-Up Study 2 — T-VASI 50 |
21.5% |
5.9% |
|
Viti-Up Study 2 — F-VASI 50 |
23.4% |
6.9% |
Fig. T-VASI 50 and F-VASI 50 Denote at Least a 50% Improvement from Baseline in the Total Vitiligo Area Scoring Index and the Face Vitiligo Area Scoring Index, Respectively. Both Viti-Up Trials Met Their Primary Endpoints.
Regulatory and Competitive Context
The EU decisions extend AbbVie’s footprint in immune-mediated skin disease, where approved systemic treatment options remain limited. Upadacitinib now carries the broadest label among the company’s immunology products, though specific patient access in individual EU member states will depend on subsequent national pricing and reimbursement processes.
Outlook
With the EU label now spanning dermatology, rheumatology, and gastroenterology indications, AbbVie continues to position upadacitinib as a franchise-level asset within its immunology portfolio. The European decisions are expected to be followed by national-level launch activities; the company has not yet disclosed a specific commercial launch timeline for either new indication.